| 1 | 60560-33-0 | 吡那地尔 | PINACIDIL | C13H19N5
| | |
| 2 | 60560-07-8 | 3-pyridyl pinacidil | 3-pyridyl pinacidil | C13H19N5
| | |
| 3 | 1206825-36-6 | Tofacitinib Impurity 3 | Tofacitinib Impurity 3 | C13H19N5
| 杂质对照品;对照品-杂质对照品 | |
| 4 | 2374700-39-5 | Tofacitinib Impurity 44 | Tofacitinib Impurity 44 | C13H19N5
| 076-托法替尼 | |
| 5 | 919730-72-6 | N-cyclooctyl-7H-purin-6-amine | N-cyclooctyl-7H-purin-6-amine | C13H19N5
| | |
| 6 | | 6-Cyclohexylamino-9-ethyl-9H-purine | 6-Cyclohexylamino-9-ethyl-9H-purine | C13H19N5
| | |
| 7 | | 2-(2-Adamantylamino)-4-amino-1,3,5-triazine | 2-(2-Adamantylamino)-4-amino-1,3,5-triazine | C13H19N5
| | |
| 8 | 195252-07-4 | 9H-Purin-6-amine, 9-cyclohexyl-N,N-dimethyl- | 9H-Purin-6-amine, 9-cyclohexyl-N,N-dimethyl- | C13H19N5
| | |
| 9 | 723753-82-0 | 1-BUTYL-N-(4-METHYLBENZYL)-1H-TETRAZOL-5-AMINE | 1-BUTYL-N-(4-METHYLBENZYL)-1H-TETRAZOL-5-AMINE | C13H19N5
| | |
| 10 | 880865-59-8 | 1-butyl-N-(2-methylbenzyl)-1H-tetraazol-5-amine | 1-butyl-N-(2-methylbenzyl)-1H-tetraazol-5-amine | C13H19N5
| | |
| 11 | | N-(4-(DIETHYLAMINO)BENZYL)-1H-1,2,4-TRIAZOL-3-AMINE | N-(4-(DIETHYLAMINO)BENZYL)-1H-1,2,4-TRIAZOL-3-AMINE | C13H19N5
| | |
| 12 | 67026-47-5 | 2-Cyano-1-(1,2-dimethylbutyl)-3-(4-pyridyl)guanidine | 2-Cyano-1-(1,2-dimethylbutyl)-3-(4-pyridyl)guanidine | C13H19N5
| | |
| 13 | | N-(4-ethylbenzyl)-N-(1-propyl-1H-tetraazol-5-yl)amine | N-(4-ethylbenzyl)-N-(1-propyl-1H-tetraazol-5-yl)amine | C13H19N5
| | |
| 14 | | N-(2-methylpentyl)-4-(1H-1,2,3,4-tetrazol-1-yl)aniline | N-(2-methylpentyl)-4-(1H-1,2,3,4-tetrazol-1-yl)aniline | C13H19N5
| | |
| 15 | 60560-40-9 | 2-Cyano-3-(4-pyridyl)-1-(1,1,2-trimethylpropyl)guanidine | 2-Cyano-3-(4-pyridyl)-1-(1,1,2-trimethylpropyl)guanidine | C13H19N5
| | |
| 16 | | butyl({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | butyl({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | C13H19N5
| | |
| 17 | | N-(3-methylpentan-2-yl)-4-(1H-1,2,3,4-tetrazol-1-yl)aniline | N-(3-methylpentan-2-yl)-4-(1H-1,2,3,4-tetrazol-1-yl)aniline | C13H19N5
| | |
| 18 | | 2-Cyano-3-(4-pyridyl)-1-[(R)-1,2,2-trimethylpropyl]guanidine | 2-Cyano-3-(4-pyridyl)-1-[(R)-1,2,2-trimethylpropyl]guanidine | C13H19N5
| | |
| 19 | | butan-2-yl({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | butan-2-yl({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | C13H19N5
| | |
| 20 | | N''-Cyano-N-(3-pyridyl)-N'-[(S)-1,2,2-trimethylpropyl]guanidine | N''-Cyano-N-(3-pyridyl)-N'-[(S)-1,2,2-trimethylpropyl]guanidine | C13H19N5
| | |
| 21 | | N-Cyano-N'-(4-pyridinyl)-N''-[(S)-1,2,2-trimethylpropyl]guanidine | N-Cyano-N'-(4-pyridinyl)-N''-[(S)-1,2,2-trimethylpropyl]guanidine | C13H19N5
| | |
| 22 | | (2-methylpropyl)({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | (2-methylpropyl)({1-[3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]ethyl})amine | C13H19N5
| | |
| 23 | 575461-46-0 | 3A,4,5,6,7,7A-六氢-1H-苯并咪唑-2-基-(4,6-二甲基嘧啶-2-基)胺 | 4,6-Dimethyl-N-(octahydro-2H-benzimidazol-2-ylidene)pyrimidin-2-amine | C13H19N5
| | |
| 24 | | 1-methyl-N-{[1,2,4]triazolo[3,4-a]pyridin-3-ylmethyl}piperidin-4-amine | 1-methyl-N-{[1,2,4]triazolo[3,4-a]pyridin-3-ylmethyl}piperidin-4-amine | C13H19N5
| | |
| 25 | 2612339-47-4 | 1,4-Cyclohexanediamine, N1-methyl-N1-7H-pyrrolo[2,3-d]pyrimidin-4-yl-, trans- | 1,4-Cyclohexanediamine, N1-methyl-N1-7H-pyrrolo[2,3-d]pyrimidin-4-yl-, trans- | C13H19N5
| | |
| 26 | 477600-74-1 | N-甲基-N-((3R,4R)-4-甲基-3-哌啶基)-7H-吡咯并[2,3-D]嘧啶-4-胺 | N-methyl-N-[(3R,4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | C13H19N5
| 标准品;医药原料;医用原料;医药中间体;杂质对照品;托法替尼杂质;托法替布中间体;托法替尼中间体;076-托法替尼 | |
| 27 | 2378663-15-9 | 托法替尼杂质70 | 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3S,4R)-4-methyl-3-piperidinyl]- | C13H19N5
| | |
| 28 | | N-(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)-N-(4,6-dimethyl-2-pyrimidinyl)amine | N-(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)-N-(4,6-dimethyl-2-pyrimidinyl)amine | C13H19N5
| | |